Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

ate to the effect that the Interim Report gives a true and fair view of the Company's assets and liabilities, financial position, results of operations and cash flows. Furthermore, we consider the Interim Report to give a true and fair statement of the developments in the Group's activities and financial affairs, results of operations and the Company's financial position as a whole as well as a description of the significant risks and uncertainties the Company faces.


    Board of Executives


        Soren Tulstrup      Henrik Stage

        President & CEO     Vice President & CFO


    Board of Directors


        Flemming         Walter         Claus          Soren Carlsen
        Ornskov          Wenninger      Braestrup

        Chairman         Vice Chairman  Director       Director



        Edwin de Graaf   Anders Hinsby  Martien van    Holger
                                        Osch           Reithinger

        Director         Director       Director       Director

Santaris Pharma forward looking statements

This written announcement contains forward-looking statements, identified by the use of words such as "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in this announcement. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of and future demand for Santaris Pharma products and the impact of competitive products and pricing. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statemen
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... it has granted to German life sciences entrepreneurs ... and commercialization of biotechnology (collectively, the "Optionee"), an ... allogenic tumor vaccine technology (the "Technology"), including AEZS-120, ... which is ready to enter a Phase 1 ...
(Date:7/27/2015)... CHICAGO and FRANKLIN, Tenn. ... Inc. ("Capella"), a privately-owned  premier provider of health care ... companies in the U.S., today announced that its ... has signed a definitive agreement with Medical Properties ... the acquisition of Capella for $900 million in cash.  The ...
(Date:7/27/2015)... MONTREAL , July 27, 2015   ... that produces sustainable biological accelerators for farmers, has ... Patent and Trademark Office for its patent application ... that accelerate plant growth and enhance yields on ... patent relates to Inocucor,s live IN-M1 microbial consortium ...
(Date:7/27/2015)... 27, 2015 Junto Health, a company that ... and develop new technology solutions, today announced the launch ... a leader in health care policy consulting. Working together ... a collaborative innovation process while, at the same time, ... public policy, health care finance and the delivery of ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... PHILADELPHIA Humans produce billions of clot-forming platelets every ... of them, such as with certain diseases or during ... that a single drug can induce bone marrow cells ... produce. Jae-Won Shin, a graduate student of pharmacology ...
... nanotubes, developed by MIT researchers, shows promise as an innovative ... Storing the sun,s heat in chemical form rather ... in a heavily insulated container has significant advantages, since ... periods of time without losing any of its stored energy. ...
... 13, 2011 International Isotopes Inc. (OTC Bulletin ... is pleased to announce it has selected Parsons ... management services firm, as the prime contractor for ... facility in Lea County, New Mexico.   The ...
Cached Biology Technology:Penn researchers show single drug and soft environment can increase platelet production 2Penn researchers show single drug and soft environment can increase platelet production 3MIT research update: New way to store sun's heat 2MIT research update: New way to store sun's heat 3International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 2International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 3International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 4
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... particles one-billionth of a meter in size can be ... brain cancer. What's more, these nanoparticles can be used ... them, according to researchers at the University of Michigan ... Photofrin along with iron oxide into nanoparticles that would ...
... soul," corneas are the panes in those windows. They shield ... the eye's outermost lens, contributing up to 75 percent of ... at the annual meeting of the American Chemical Society, chemical ... that's finding its way into artificial corneas. It's a hydrogel, ...
... in monoclonal antibody research for oncology offers a ... of antibody therapies against solid tumors. Writing in ... http://www.interscience.wiley.com/cancer-newsroom ), a peer-reviewed journal of the American ... of cancers involve solid tumors, but only 25 ...
Cached Biology News:U-M researchers use nanoparticles to target brain cancer 2U-M researchers use nanoparticles to target brain cancer 3An artificial cornea is in sight, thanks to biomimetic hydrogels 2An artificial cornea is in sight, thanks to biomimetic hydrogels 3An artificial cornea is in sight, thanks to biomimetic hydrogels 4Report calls for improved monoclonal antibodies against solid tumors 2
... If particles in the submicron range ... development process, measurement and control of particle ... an analyzer that can reliably detect the ... The N5 Submicron Particle Size Analyzer uses ...
... High, 400 ng IgG/cm 2 (1cm2 ... Hydrophobic/Ionic , Performance Certified: Well-to-Well, CV =3% ... Well Volume: 360 µl , Packaging: 5 ... Special optically clear polystyrene formulation , High ...
... Second Mitochondria Derived Activator of Caspase/DIABLO ... pH 7.5 AVOID FREEZE/THAW CYCLES. Amino acid residues ... carboxy terminal His•Tag ® sequence was expressed ... Smac/DIABLO is released along with cytochrome c ...
... JASCO offers a dedicated system for ... modular LC-1500 series of HPLC instrumentation. JASCO ... enhance the capability of the system: ,- ... chromatography and extraction procedures using carbon dioxide ...
Biology Products: